Others are faster growing ('aggressive'), for example, diffuse large B-cell lymphoma, Burkitt’s lymphoma and mantle cell lymphoma. Roche’s heritage in non-hodgkin lymphoma treatment Rituximab ...

The direct antiglobulin test was positive for anti-C3d specificity, with cold agglutinin titer confirming the diagnosis of CAD.

Cancer survivor Zoe Plastiras hopes her message provides some reassurance by highlighting advances in cancer treatment.

Three subtypes have been identified by gene-expression studies; germinal center (GC) DLBCL, non-GC DLBCL, and mediastinal large B-cell lymphoma. GC and non-GC DLBCL differ with respect to the cell ...

Yescarta (axicabtagene ciloleucel) has been approved as a treatment for adults with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) and primary mediastinal large B-cell lymphoma ...

high grade B-cell lymphoma, primary mediastinal large B-cell lymphoma and FL grade 3B. The application is supported by data ...

Ultrasensitive detection of circulating tumor DNA can improve clinical outcomes in aggressive B-cell lymphomas by identifying measurable ... Prognostic value of interim FDG-PET in diffuse large cell ...

The CHMP recommends approval of Bristol Myers' Opdivo plus Yervoy for the first-line treatment of hepatocellular carcinoma ...

Ann LaCasce, MD, MMSc, delved into some of the most recent advances in the lymphoma space, exploring how these new therapies ...